MajesTEC-1 Results Show Efficacy for Teclistamab in Multiple Myeloma
May 9th 2023In a live virtual event, Jens Hillengass discussed the results of the MajesTEC-1 study and how teclistamab is used to treat patients with relapsed/refractory multiple myeloma. This is the second article in a 2-article series on this case.
Nivolumab/Relatlimab Shows PFS/OS Benefit Over Nivolumab in Melanoma
May 5th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed data from the RELATIVITY-047 trial of nivolumab plus relatlimab for patients with metastatic melanoma. This is the second of 2 articles based on this event.
Choosing Between Tivozanib and Lenvatinib/Everolimus in Third-Line RCC
May 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Randy F. Sweis, MD, discussed with participants their experiences using tivozanib and lenvatinib/everolimus in patients who have received at least 2 prior lines of therapy for advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Real-World Factors Influence Choice of IO/TKI Regimen for mRCC
May 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants what real-world patient conditions would impact their choice of frontline therapy for metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
Amivantamab Compared With Real-World EGFR Exon 20 NSCLC Population
April 26th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed research supporting the use of amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion, including data comparing with real-world cohorts of similar patients treated with other agents.
Physicians Discuss Role of Elacestrant in ER+ Metastatic Breast Cancer
April 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Claudine Isaacs, MD, discussed with participants their reactions to the data from the phase 3 EMERALD study of elacestrant for patients with metastatic ER+ breast cancer.
Roundtable Discussion: Khan Reviews Systemic Therapy for Relapsed/Refractory DLBCL
April 24th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Cyrus Khan, MD, discussed the case of a patient with relapsed/refractory diffuse large B-cell lymphoma who was referred for chimeric antigen receptor T-cell therapy and was place on a waiting list for treatment.
DiSilvestro Looks at PARP Inhibition as First-Line Maintenance Therapy in Advanced Ovarian Cancer
April 23rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Paul D. DiSilvestro, MD, discussed the key trials supporting the use of PARP inhibitor maintenance therapy for patients with advanced ovarian cancer.
Oncology Nurses Discuss Adverse Event Management in mRCC Treatment
April 22nd 2023During a live virtual event, Sarah Yenser Wood, RN, MSN, ANP, AOCNP, and a panel of oncology nurses discussed their approaches to management of patients receiving first-line regimens for advanced or metastatic renal cell carcinoma.
Efficacy and Tolerability of Immunotherapies Discussed for Melanoma
April 20th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed with other oncologists what efficacy and safety data aid them in choosing an immunotherapy regimen for patients with metastatic melanoma. This is the first of 2 articles based on this event.
Langer Assesses Several Targeted Treatment Options in the Non–Small Cell Lung Cancer Landscape
April 19th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Corey J. Langer, MD, discussed the EMPOWER Lung-3 and POSEIDON trials of immunotherapy options in patients with non–small cell lung cancer.
Roundtable Discussion: Zakharia Considers Next-Line Therapy Sequencing for mCRPC
April 17th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Yousef Zakharia, MD, discussed next-line therapy for a patient with metastatic castration-resistant prostate cancer who has received docetaxel and an androgen receptor–targeted therapy.
Sborov Looks at Combination Therapies in Relapsed/Refractory Multiple Myeloma
April 16th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Douglas W. Sborov, MD, MS, discussed possible therapy options for a patient who relapsed after receiving bortezomib, lenalidomide, and dexamethasone followed by autologous stem cell transplant.
Reviewing Key Efficacy and Safety Data for Tafasitamab Plus Lenalidomide in DLBCL
April 14th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Gilles Salles, MD, discussed the study results and practical considerations for the use of tafasitamab plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Roundtable Discussion: Bodor Reviews Benefits, Challenges of Immunotherapy for Squamous NSCLC
April 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, J. Nicholas Bodor, MD, PhD, MPH, discussed the CheckMate 9LA regimen of nivolumab and ipilimumab plus chemotherapy for patients with advanced squamous non–small cell lung cancer.
Discussing the Future Role of Stem Cell Transplant in Multiple Myeloma
April 12th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Surbhi Sidana, MD, discussed with participants their thoughts on the future of transplantation in multiple myeloma. This is the second of 2 articles based on this event.
Dosing Considerations for Selinexor in R/R Multiple Myeloma
April 10th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua Richter, MD, discussed considerations when using selinexor with various drug combinations in later-line multiple myeloma therapy. This is the second of 2 articles based on this event.
Clinical Commentary: Tawbi Assesses Toxicities of Therapies in Advanced Melanoma
April 10th 2023During a live webinar, Hussein Tawbi, MD, PhD, discussed first-line therapy for patients with stage IV melanoma, particularly the impact of targeting both PD-1 and LAG3 in these patients by using nivolumab and relatlimab.
Roundtable Discussion: Carraway Assesses Remaining Challenges in BPDCN Patient Population
April 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Hetty E. Carraway, MD, MBA, discussed with participants diagnosing and treating patients with BPDCN, as well as the remaining challenges in this space.